Ask AI
ProCE Banner Series

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Follicular Lymphoma

All Events

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Upcoming Events

August

06

2025

12:00 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Incyte